Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620776 · ClinicalTrials.gov registry record · Phase 2
Combined Treatment for Generalized Anxiety Disorder (GAD)
A Phase 2 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT00620776 is a Phase 2 study of Generalized Anxiety Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 69 participants, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00620776, a Phase 2 study of Generalized Anxiety Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD). The general goals of the current study are to conduct a late stage treatment development study. The goal of this stage of research is to provide a preliminary answer to the question and to gather data to estimate intervention parameters (e.g., effect size, attrition rates, response rates) that would assist in planning further research.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- DRUG Venlafaxine XR
Study Locations (1)
Pennsylvania
- University of Pennsylvania, 3535 Market Street, Suite 650 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620776
The ClinicalTrials.gov registry entry for NCT00620776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (68% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT00620776 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00620776 about?
NCT00620776 is a clinical study titled "Combined Treatment for Generalized Anxiety Disorder (GAD)". The purpose of this study is to conduct a preliminary evaluation of the efficacy of combined medication and psychotherapy for generalized anxiety disorder (GAD). The general goals of the current study are to conduct a late stage treatment development study. The goal of this stage of research is to p...
What is the current status of trial NCT00620776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2006-10. Estimated completion is 2008-03.
What conditions does trial NCT00620776 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00620776?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT00620776?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00620776 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Use of CBD in the Treatment of Anxiety
RECRUITING · Phase 2
-
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
RECRUITING · Phase 2
-
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
ACTIVE NOT RECRUITING · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.